title: Progression-free survival in neuroendocrine tumors: preferred end point, but how should it be defined?
authors.forename: Rachel P
authors.initials: RP
authors.lastname: Riechelmann
authors.forename: Juliana
authors.initials: J
authors.lastname: Rego
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004341:Drug Evaluation / Q000379:methods*; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D015203:Reproducibility of Results
chemical_list: D000970:Antineoplastic Agents